Ovarian Cancer Management: The role of imaging and diagnostic challenges

European Journal of Radiology

Volumn 78, Issue 1, 2011, Pages 41-51

  Bharwani, Nishat ^a,b   Reznek, Rodney H ^a   Rockall, Andrea G ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Computed tomography; Magnetic resonance imaging; Ovarian cancer; PET CT; Recurrent disease; Ultrasound

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PLATINUM;

ADJUVANT CHEMOTHERAPY; ADNEXA DISEASE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DOPPLER FLOWMETRY; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; ULTRASOUND;

BIOPSY; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FEMALE; FORECASTING; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 79954802124     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2010.11.039     Document Type: Review

References (95)

1. Cancer Research UK - Cancer Stats website - ovarian cancer survival. http://info.cancerresearchuk.org/cancerstats/ [accessed May 2010].
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 58 2 2008 71 96
3. D. Grab, F. Flock, and I. Stohr Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography Gynecol Oncol 77 3 2000 454 459 (Pubitemid 30368567)
4. J.L. Benedet, H. Bender, H.J.III Jones, H.Y. Ngan, and S. Pecorelli FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 70 2 2000 209 262
5. F.L. Greene, D.L. Page, and I.D. Fleming Gynecological sites AJCC Cancer Staging Manual 2002 Springer pp. 275-283
6. SEER Cancer Data. http://seer.cancer.gov/statfacts/ [accessed May 2010].
7. R.E. Scully World Health Organization classification and nomenclature of ovarian cancer Natl Cancer Inst Monogr 42 1975 5 7
8. Ovarian Tumour Panel of the Royal College of Obstetricians and Gynaecologists Ovarian epithelial tumours of borderline malignancy: pathological features and current status BJOG 90 8 1983 743 750
9. D. Lowe The pathological features of ovarian neoplasia R.H. Reznek, Cancer of the ovary 2007 Cambridge University Press Cambridge 20 46
10. A.R. Mayer, S.K. Chambers, and E. Graves Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 47 2 1992 223 227 (Pubitemid 23001332)
11. E.J. Junor, D.J. Hole, L. McNulty, M. Mason, and J. Young Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients Br J Obstet Gynaecol 106 11 1999 1130 1136 (Pubitemid 29495411)
12. M.E. Carney, J.M. Lancaster, C. Ford, A. Tsodikov, and C.L. Wiggins A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84 1 2002 36 42 (Pubitemid 34056463)
13. J. Webb Ultrasound in ovarian carcinoma R.H. Reznek, Cancer of the ovary 2007 Cambridge University Press Cambridge 94 111
14. K. Kinkel, Y. Lu, A. Mehdizade, M.F. Pelte, and H. Hricak Indeterminate ovarian mass at US: incremental value of second imaging test for characterization - meta-analysis and Bayesian analysis Radiology 236 1 2005 85 94 (Pubitemid 40853299)
15. S. Granberg Relationship of macroscopic appearance to the histologic diagnosis of ovarian tumors Clin Obstet Gynecol 36 2 1993 363 374 (Pubitemid 23133169)
16. R.V. Higgins, N.J. van Jr., and E.S. Donaldson Transvaginal sonography as a screening method for ovarian cancer Gynecol Oncol 34 3 1989 402 406
17. Y.Y. Jeong, E.K. Outwater, and H.K. Kang Imaging evaluation of ovarian masses Radiographics 20 5 2000 1445 1470
18. S. Granberg, M. Wikland, and I. Jansson Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation Gynecol Oncol 35 2 1989 139 144 (Pubitemid 19268545)
19. E. Ekerhovd, H. Wienerroith, A. Staudach, and S. Granberg Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis Am J Obstet Gynecol 184 2 2001 48 54 (Pubitemid 32141641)
20. J.P. Lerner, I.E. Timor-Tritsch, A. Federman, and G. Abramovich Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system Am J Obstet Gynecol 170 1 (Pt 1) 1994 81 85 (Pubitemid 24084035)
21. D. Timmerman, A.C. Testa, and T. Bourne Simple ultrasound-based rules for the diagnosis of ovarian cancer Ultrasound Obstet Gynecol 31 6 2008 681 690
22. K. Kinkel, H. Hricak, Y. Lu, K. Tsuda, and R.A. Filly US characterization of ovarian masses: a meta-analysis Radiology 217 3 2000 803 811
23. S. Guerriero, J.L. Alcazar, and S. Ajossa Comparison of conventional color Doppler imaging and power Doppler imaging for the diagnosis of ovarian cancer: results of a European study Gynecol Oncol 83 2 2001 299 304 (Pubitemid 33033070)
24. S. Adusumilli, H.K. Hussain, and E.M. Caoili MRI of sonographically indeterminate adnexal masses Am J Roentgenol 187 3 2006 732 740 (Pubitemid 44651498)
25. I. Jacobs, D. Oram, J. Fairbanks, J. Turner, C. Frost, and J.G. Grudzinskas A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 10 1990 922 929 (Pubitemid 20340625)
26. S. Tingulstad, B. Hagen, and F.E. Skjeldestad Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses Br J Obstet Gynaecol 103 8 1996 826 831 (Pubitemid 26291762)
27. J. Bailey, A. Tailor, and R. Naik Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 16 Suppl. 1 2006 30 34
28. P.O. van Trappen, B.D. Rufford, and T.D. Mills Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy Int J Gynecol Cancer 17 1 2007 61 67 (Pubitemid 46213971)
29. A.N. Rosenthal, U. Menon, and I.J. Jacobs Screening for ovarian cancer Clin Obstet Gynecol 49 3 2006 433 447 (Pubitemid 44181417)
30. UKCTOCS. http://www.ukctocs.org.uk/ [accessed May 2010].
31. NIH PLCO. http://prevention.cancer.gov/programs-resources/groups/ed/ programs/plco [accessed May 2010].
32. H. Hricak, M. Chen, and F.V. Coakley Complex adnexal masses: detection and characterization with MR imaging - multivariate analysis Radiology 214 1 2000 39 46 (Pubitemid 30019867)
33. A.B. Kurtz, J.V. Tsimikas, and C.M. Tempany Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US CT, and MR imaging correlated with surgery and histopathologic analysis - report of the Radiology Diagnostic Oncology Group Radiology 212 1 1999 19 27 (Pubitemid 29302506)
34. S.A. Sohaib, T.D. Mills, and A. Sahdev The role of magnetic resonance imaging and ultrasound in patients with adnexal masses Clin Radiol 60 3 2005 340 348 (Pubitemid 40260268)
35. S.A. Sohaib, and R.H. Reznek MR imaging in ovarian cancer R.H. Reznek, Cancer of the ovary 2007 Cambridge University Press Cambridge 112 131
36. S.A. Sohaib, and R.H. Reznek MR imaging in ovarian cancer Cancer Imaging 7 Spec No A 2007 S119 S129
37. S.A. Sohaib, A. Sahdev, P. Van Trappen, I.J. Jacobs, and R.H. Reznek Characterization of adnexal mass lesions on MR imaging Am J Roentgenol 180 5 2003 1297 1304 (Pubitemid 36504618)
38. C.M. Tempany, K.H. Zou, S.G. Silverman, D.L. Brown, A.B. Kurtz, and B.J. McNeil Staging of advanced ovarian cancer: comparison of imaging modalities - report from the Radiological Diagnostic Oncology Group Radiology 215 3 2000 761 767 (Pubitemid 30346013)
39. J. Zhang, S. Mironov, and H. Hricak Characterization of adnexal masses using feature analysis at contrast-enhanced helical computed tomography J Comput Assist Tomogr 32 4 2008 533 540
40. J.A. Spencer, R. Forstner, and H. Hricak Investigating women with suspected ovarian cancer Gynecol Oncol 108 2 2008 262 264 (Pubitemid 351174288)
41. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 5 2002 1248 1259 (Pubitemid 34177431)
42. R.W. Hunter, N.D. Alexander, and W.P. Soutter Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166 2 1992 504 511
43. M.E. Potter, E.E. Partridge, K.D. Hatch, S.J. Soong, J.M. Austin, and H.M. Shingleton Primary surgical therapy of ovarian cancer: how much and when Gynecol Oncol 40 3 1991 195 200
44. S.C. Crawford, P.A. Vasey, J. Paul, A. Hay, J.A. Davis, and S.B. Kaye Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 34 2005 8802 8811 (Pubitemid 46211526)
45. S.M. Eisenkop, R.L. Friedman, and H.J. Wang Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study Gynecol Oncol 69 2 1998 103 108 (Pubitemid 28246994)
46. J.Y. Hou, M.G. Kelly, and H. Yu Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 1 2007 211 217 (Pubitemid 46441463)
47. W. Kuhn, S. Rutke, and K. Spathe Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma Cancer 92 10 2001 2585 2591 (Pubitemid 33049442)
48. A. Onnis, M. Marchetti, P. Padovan, and L. Castellan Neoadjuvant chemotherapy in advanced ovarian cancer Eur J Gynaecol Oncol 17 5 1996 393 396 (Pubitemid 26381529)
49. P.E. Schwartz, T.J. Rutherford, J.T. Chambers, E.I. Kohorn, and R.P. Thiel Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival Gynecol Oncol 72 1 1999 93 99 (Pubitemid 29045454)
50. K. Ushijima, S. Ota, and K. Komai Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer Int Surg 87 3 2002 185 190
51. I. Vergote, W. De, I. Tjalma, W. Van Gramberen, M. Decloedt, and J.P. van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 3 1998 431 436 (Pubitemid 29022333)
52. I.B. Vergote, W. De, I. Decloedt, J. Tjalma, W. Van Gramberen, and M.P. van Dam Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer Semin Oncol 27 3 Suppl. 7 2000 31 36 (Pubitemid 30643850)
53. M.U. Vrscaj, and S. Rakar Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study Eur J Gynaecol Oncol 23 5 2002 405 410 (Pubitemid 35364667)
54. EORTC 55971. http://www.eortc.be/protoc/details.asp?protocol=55971 [accessed May 2010].
55. CHORUS. http://www.ctu.mrc.ac.uk/studies/CHORUS.asp [accessed May 2010].
56. EORTC-GCG/NCIC-CTG Randomised Trial Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy In Stage IIIC-IV Ovarian, Fallopian Tube And Peritoneal Cancer (OVCA) 2008
57. R. Forstner, H. Hricak, K.A. Occhipinti, C.B. Powell, S.D. Frankel, and J.L. Stern Ovarian cancer: staging with CT and MR imaging Radiology 197 3 1995 619 626
58. E.K. Outwater, and C.J. Dunton Imaging of the ovary and adnexa: clinical issues and applications of MR imaging Radiology 194 1 1995 1 18 (Pubitemid 24380913)
59. S.K. Stevens, H. Hricak, and Z. Campos Teratomas versus cystic hemorrhagic adnexal lesions: differentiation with proton-selective fat-saturation MR imaging Radiology 186 2 1993 481 488 (Pubitemid 23033877)
60. D.G. Mitchell, M.C. Hill, S. Hill, and C. Zaloudek Serous carcinoma of the ovary: CT identification of metastatic calcified implants Radiology 158 3 1986 649 652 (Pubitemid 16101251)
61. A. Sahdev, J.H. Hughes, T. Barwick, A.G. Rockall, C.J. Gallagher, and R.H. Reznek Computed tomography features of recurrent ovarian carcinoma according to time to relapse Acta Radiol 48 9 2007 1038 1044 (Pubitemid 350023001)
62. A.D. Levy, J. Arnaiz, J.C. Shaw, and L.H. Sobin From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation Radiographics 28 2 2008 583 607
63. A.E. Axtell, M.H. Lee, and R.E. Bristow Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer J Clin Oncol 25 4 2007 384 389 (Pubitemid 350002986)
64. J.I. Meyer, A.W. Kennedy, R. Friedman, A. Ayoub, and R.C. Zepp Ovarian carcinoma: value of CT in predicting success of debulking surgery Am J Roentgenol 165 4 1995 875 878
65. B.E. Nelson, A.T. Rosenfield, and P.E. Schwartz Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma J Clin Oncol 11 1 1993 166 172 (Pubitemid 23059991)
66. R.C. Semelka, P.H. Lawrence, J.P. Shoenut, M. Heywood, M.A. Kroeker, and R. Lotocki Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre-and postcontrast, fat-suppressed MR imaging, with histologic correlation J Magn Reson Imaging 3 1 1993 99 106
67. R.E. Bristow, L.R. Duska, and N.C. Lambrou A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer 89 7 2000 1532 1540
68. A. Qayyum, F.V. Coakley, A.C. Westphalen, H. Hricak, W.T. Okuno, and B. Powell Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer Gynecol Oncol 96 2 2005 301 306 (Pubitemid 40127125)
69. R. Salani, A. Axtell, M. Gerardi, C. Holschneider, and R.E. Bristow Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer Gynecol Oncol 108 2 2008 271 275
70. National Cancer Institute Recommendation. http://ctep.cancer.gov/ highlights/docs/clin-annc010506.pdf [accessed May 2010].
71. D.S. Chi, P.T. Ramirez, and J.B. Teitcher Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less J Clin Oncol 25 31 2007 4946 4951 (Pubitemid 350220426)
72. J.A. Spencer, S.E. Swift, N. Wilkinson, A.P. Boon, G. Lane, and T.J. Perren Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care Radiology 221 1 2001 173 177 (Pubitemid 32880385)
73. D.L. Brown, K.H. Zou, and C.M. Tempany Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study Radiology 219 1 2001 213 218 (Pubitemid 32234076)
74. M.J. Hewitt, G.D. Hall, N. Wilkinson, T.J. Perren, G. Lane, and J.A. Spencer Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis Int J Gynecol Cancer 16 Suppl. 1 2006 108 110
75. S.A. Funt, H. Hricak, N. Abu-Rustum, M. Mazumdar, H. Felderman, and D.S. Chi Role of CT in the management of recurrent ovarian cancer Am J Roentgenol 182 2 2004 393 398 (Pubitemid 38116581)
76. S.A. Cannistra, R.C. Bast Jr., and J.S. Berek Progress in the management of gynecologic cancer: consensus summary statement J Clin Oncol 21 10 Suppl. 2003 129s 132s
77. P. Harter, and A. du Bois The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence Curr Opin Oncol 17 5 2005 505 514 (Pubitemid 41224935)
78. S.M. Eisenkop, R.L. Friedman, and N.M. Spirtos The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma Cancer 88 1 2000 144 153 (Pubitemid 30027690)
79. S. Fenchel, D. Grab, and K. Nuessle Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings Radiology 223 3 2002 780 788 (Pubitemid 34547598)
80. Y. Yoshida, T. Kurokawa, and K. Kawahara Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer Am J Roentgenol 182 1 2004 227 233 (Pubitemid 38017747)
81. M. Zimny, W. Siggelkow, and W. Schroder 2-[Fluorine-18]-fluoro-2-deoxy-d- glucose positron emission tomography in the diagnosis of recurrent ovarian cancer Gynecol Oncol 83 2 2001 310 315 (Pubitemid 33033072)
82. R.B. Iyer, A. Balachandran, and C.E. Devine PET/CT and cross sectional imaging of gynecologic malignancy Cancer Imaging 7 Spec No A 2007 S130 S138
83. W.C. Chang, Y.C. Hung, C.H. Kao, R.F. Yen, Y.Y. Shen, and C.C. Lin Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker Neoplasma 49 5 2002 329 333 (Pubitemid 35434597)
84. Y. Nakamoto, T. Saga, and T. Ishimori Clinical value of positron emission tomography with FDG for recurrent ovarian cancer Am J Roentgenol 176 6 2001 1449 1454 (Pubitemid 32510262)
85. M. Picchio, S. Sironi, and C. Messa Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment Q J Nucl Med 47 2 2003 77 84 (Pubitemid 36998713)
86. C. Nanni, D. Rubello, and M. Farsad (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients Eur J Surg Oncol 31 7 2005 792 797 (Pubitemid 41194659)
87. M.M. Thrall, J.A. DeLoia, H. Gallion, and N. Avril Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer Gynecol Oncol 105 1 2007 17 22 (Pubitemid 46441448)
88. R.E. Bristow, M.G. del Carmen, and H.K. Pannu Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT Gynecol Oncol 90 3 2003 519 528
89. Y. Nishiyama, Y. Yamamoto, and K. Kanenishi Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET Eur J Nucl Med Mol Imaging 35 2 2008 287 295
90. N. Avril, S. Sassen, and B. Schmalfeldt Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer J Clin Oncol 23 30 2005 7445 7453 (Pubitemid 46291806)
91. A. Musto, L. Rampin, C. Nanni, M.C. Marzola, S. Fanti, and D. Rubello Present and future of PET and PET/CT in gynaecologic malignancies Eur J Radiol 2010
92. E. Sala, A.N. Priest, and M. Kataoka Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development Eur Radiol 20 2 2010 491 496
93. A.J. Gunn, Y. Hama, Y. Koyama, E.C. Kohn, P.L. Choyke, and H. Kobayashi Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore Cancer Sci 98 11 2007 1727 1733 (Pubitemid 47487908)
94. M.R. Longmire, M. Ogawa, and Y. Hama Determination of optimal rhodamine fluorophore for in vivo optical imaging Bioconjug Chem 19 8 2008 1735 1742
95. N. Kosaka, M. Ogawa, M.R. Longmire, P.L. Choyke, and H. Kobayashi Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer J Biomed Opt 14 1 2009 014023